TC Biopharm (Holdings) Plc (TCBP) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Motherwell, 영국. 현재 CEO는 Bryan Leland Kobel.
TCBP 을(를) 보유 IPO 날짜 2022-02-11, 41 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $256.5K.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
